These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11890872)

  • 1. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Opin Biol Ther; 2002 Mar; 2(3):335-42. PubMed ID: 11890872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous, hapten-modified vaccine as a treatment for human cancers.
    Berd D
    Vaccine; 2001 Mar; 19(17-19):2565-70. PubMed ID: 11257393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous, hapten-modified vaccine as a treatment for human cancers.
    Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
    Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
    Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
    J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
    Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
    Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
    Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
    Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
    Sato T
    Cancer Immunol Immunother; 1996 Nov; 43(3):174-9. PubMed ID: 9001571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
    Berd D
    Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
    Berd D; Sato T; Mastrangelo MJ
    Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
    Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
    J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
    Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E
    Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D; Maguire HC; McCue P; Mastrangelo MJ
    J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.
    Sato T; Maguire HC; Mastrangelo MJ; Berd D
    Clin Immunol Immunopathol; 1995 Jan; 74(1):35-43. PubMed ID: 7994925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model.
    Sojka DK; Felnerova D; Mokyr MB
    Cancer Immunol Immunother; 2002 Jun; 51(4):200-8. PubMed ID: 12012107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.
    Lotem M; Shiloni E; Pappo I; Drize O; Hamburger T; Weitzen R; Isacson R; Kaduri L; Merims S; Frankenburg S; Peretz T
    Br J Cancer; 2004 Feb; 90(4):773-80. PubMed ID: 14970852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portrait of an autologous cancer vaccine: Then and now.
    Berd D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2172925. PubMed ID: 36755486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
    Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
    Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.